Category Archives: Ones to Watch

Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch”

Oncology pipeline features significant safety/efficacy advantages Lead candidate poised for FDA acceleration due to significant unmet need in AML Broad-spectrum applicability of WP1066 & WP1122 portfolios of molecules For preclinical oncology biopharma Moleculin Biotech, Inc. (NASDAQ: MBRX), the quest to deliver potentially revolutionary anti-cancer drugs to the market is enkindled by a close association with […]

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is “One to Watch”

With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ: AZRX) core science team is the real strength behind the company’s developing portfolio of recombinant therapies. AzurRx […]

FORM Holdings Corp. (NASDAQ: FH) is “One to Watch”

FORM Holdings (NASDAQ: FH) employs a relatively simple yet extremely robust targeting matrix when it comes to acquiring new development candidates. It’s really all about what this diverse holding company can bring to table, as well as how much an otherwise promising, vetted target can benefit – whether it is additional capital and restructuring we […]

Revance Therapeutics, Inc. (RVNC) is “One to Watch”

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company focused on the development, commercialization, and manufacture of botulinum toxin products for use in aesthetic and therapeutic indications, including dermatology and neurology, recently announced its operating results for the third quarter of 2016 ended September 30. A summary of the company’s financial results highlighted research and development […]

Daktronics, Inc. (DAKT) is “One to Watch”

Daktronics, Inc. (NASDAQ: DAKT), a company that designs, manufactures, and sells electronic display systems and related products on a global scale, has been the topic of several reports since the company announced breaking into a new 52-week high on November 25, 2016. ( announced shares for the company reached a peak of $10.78, closing […]

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two […]

Citius Pharmaceuticals, Inc. (CTXR) is “One to Watch”

Citius Pharmaceuticals, Inc. (OTCQB: CTXR), a specialty biopharmaceutical company that develops and commercializes therapeutics products, has been a topic of conversation among analysts since the initiation of its phase III clinical trial of Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters and treat bloodstream infections that stem from catheters. This phase […]

Stay Connected

Sign up to receive the latest market news, perspectives on clients, and ongoing DTN announcements. Via our newsletter, you will also learn highly effective marketing strategies and ways to properly exposure your brand.